Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Jump-Start Your Search For Promising Trade Ideas With Barchart Premier’s "Top Stock Pick". FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or

Affimed N.V. (AFMD)

Affimed N.V. (AFMD)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Profile for [[ item.sessionDateDisplayLong ]]

Company Info

Affimed N.V. GOTTLIEB-DAIMLER-STRASSE 2 MANNHEIM 2M 68165 DEU

www.affimed.com Employees: 78 P: 49-62-15600-30 F: 221-674-3649

Description:

Affimed N.V is a clinical stage biopharmaceutical company. It is engaged in developing single and combination therapies to treat cancers. The company's product pipeline consists of AFM13, AFM24, AFM26, AFM11 and AMV564 which are in clinical stage. Affimed N.V, formerly known as Affimed Therapeutics B.V., is based in Heidelberg, Germany.

Key Statistics

Overview:

Market Capitalization, $K 57,101
Enterprise Value, $K 28,551
Shares Outstanding, K 15,227
Annual Sales, $ 8,960 K
Annual Net Income, $ -114,660 K
Last Quarter Sales, $ 170 K
Last Quarter Net Income, $ -16,640 K
EBIT, $ -87,530 K
EBITDA, $ -85,640 K
60-Month Beta 2.10
% of Insider Shareholders 3.80%
% of Institutional Shareholders 30.82%
Float, K 14,648
% Float 96.20%
Short Volume Ratio 0.49

Growth:

1-Year Return 14.96%
3-Year Return -94.43%
5-Year Return -84.24%
5-Year Revenue Growth -68.03%
5-Year Earnings Growth -101.84%
5-Year Dividend Growth 0.00%

Per-Share Information:

Most Recent Earnings -1.09 on 09/05/24
Next Earnings Date 11/14/24 [BMO]
Earnings Per Share ttm -4.17
EPS Growth vs. Prev Qtr 21.01%
EPS Growth vs. Prev Year 50.45%
Annual Dividend Yield 0.00%
Dividend Payout Ratio 0.00%
Most Recent Split 1-10 on 03/11/24

AFMD Ratios

Ratio
Price/Earnings ttm 0.00
Price/Earnings forward N/A
Price/Earnings to Growth N/A
Return-on-Equity % -155.30%
Return-on-Assets % -92.65%
Profit Margin % -1,279.69%
Debt/Equity 0.33
Price/Sales 6.39
Price/Cash Flow N/A
Price/Book 1.85
Book Value/Share 2.03
Interest Coverage -4.30
Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.

Free Barchart Webinar